Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cartesian Therapeutics (RNAC) FCF Margin (2016 - 2026)

Cartesian Therapeutics (RNAC) has disclosed FCF Margin for 12 consecutive years, with 28453.85% as the latest value for Q1 2026.

  • For Q1 2026, FCF Margin fell 2630448.0% year-over-year to 28453.85%; the TTM value through Mar 2026 reached 8472.39%, up 859377.0%, while the annual FY2025 figure was 19848.75%, 1976314.0% down from the prior year.
  • FCF Margin hit 28453.85% in Q1 2026 for Cartesian Therapeutics, down from 1255.45% in the prior quarter.
  • Across five years, FCF Margin topped out at 1935.92% in Q3 2024 and bottomed at 28453.85% in Q1 2026.
  • Average FCF Margin over 5 years is 2028.79%, with a median of 105.65% recorded in 2022.
  • Year-over-year, FCF Margin skyrocketed 207541bps in 2024 and then tumbled -2630448bps in 2026.
  • Cartesian Therapeutics' FCF Margin stood at 71.81% in 2022, then crashed by -293bps to 282.47% in 2023, then surged by 295bps to 551.68% in 2024, then soared by 128bps to 1255.45% in 2025, then plummeted by -2366bps to 28453.85% in 2026.
  • According to Business Quant data, FCF Margin over the past three periods came in at 28453.85%, 1255.45%, and 4396.9% for Q1 2026, Q4 2025, and Q3 2025 respectively.